Cancer Support Community launches national program to assist patients with cancer

AmgenThe Cancer Support Community (CSC) and the Amgen Foundation, today announced the launch of Open to Options", a program designed to bridge the communications gap between physicians and patients and inspire patient confidence in making treatment decisions. Following a successful pilot funded by the Centers for Disease Control (CDC), the Open to Options program is ready to provide professional counselors who help more people formulate a list of personalized questions and concerns to be taken into the oncologist's office.

"The number and complexity of options for treating cancer can be overwhelming for people," said Vicki Kennedy, Vice President of Program Development & Delivery at the CSC. "The goal of Open to Options is to help people affected by all cancers evaluate their options so they can feel more confident and communicate clearly with their doctor so a decision is made that best fits their individual desires and goals."

"We are delighted to support the Open to Options program as part of our ongoing commitment to empowering patients to take an active role in their care," said Jean Lim Terra, president of the Amgen Foundation. "The resources that the Cancer Support Community provides individuals and families helps to ensure that those affected by cancer have the knowledge and support they need to make the right decisions at the right time."

The program was created in response to CSC research that found the majority of cancer patients are unprepared to make treatment decisions. A CSC pilot study funded by the Centers for Disease Control and Prevention found that 9 out of 10 patients felt that the list of questions, concerns and expectations contributed to a more productive appointment with their doctor and that the oncologist answered most of their questions. The study also showed:

  • A decrease in anxiety about the appointment for most patients
  • Repeat use of the tools and techniques learned
  • Patient and physician satisfaction

"Open to Options helped me prioritize my questions and concerns in a concise, logical order to help me optimize my time with the oncologist," said Trish H., a multiple myeloma patient who participated in the Open to Options pilot. "When I went into his office, I had my concerns printed out and when I left the appointment I knew that I had decided on the treatment option that was right for me."

About the Cancer Support Community
Backed by evidence that the best cancer care includes emotional and social support, the Cancer Support Community offers these services to all people affected by cancer. Likely the largest professionally-led network of cancer support worldwide, the organization delivers a comprehensive menu of personalized and essential services. Because no cancer care plan is complete without emotional and social support, the Cancer Support Community has a vibrant network of community-based centers and online services run by trained and licensed professionals.

In July 2009, The Wellness Community and Gilda's Club Worldwide joined forces to become the Cancer Support Community. The combined organization provides high-quality psychological and social support through a network of nearly 50 local affiliates, more than 100 satellite locations and online.

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made nearly $180 million in grants to nonprofit organizations throughout the United States, Puerto Rico and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]